UOC
DTIL icon

UBS O'Connor’s Precision BioSciences DTIL Stock Holding History

UBS O'Connor’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,534
Closed -$59.2K – 375
2024
Q4 		$59.2K Buy
15,534
+2,805
+22% +$20.5K ﹤0.01% 360
2024
Q3 		$114K Buy
12,729
+1,183
+10% +$11.4K ﹤0.01% 407
2024
Q2 		$112K Hold
11,546
– – ﹤0.01% 427
2024
Q1 		$157K Buy
11,546
+3,609
+45% +$44.2K ﹤0.01% 410
2023
Q4 		$86.9K Sell
7,937
-36,673
-82% -$395K ﹤0.01% 414
2023
Q3 		$456K Hold
44,610
– – 0.01% 410
2023
Q2 		$704K Buy
44,610
+14,082
+46% +$322K 0.01% 415
2023
Q1 		$691K Buy
+30,528
New +$1.01M 0.02% 439
2022
Q4 		– Sell
-16,417
Closed -$640K – 93
2022
Q3 		$640K Buy
16,417
+1,750
+12% +$83.1K 0.01% 788
2022
Q2 		$704K Buy
+14,667
New +$861K 0.01% 793

Other funds holding DTIL

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS O'Connor's DTIL Position: Q1 2025 in Review

UBS O'Connor sold out of Precision BioSciences (DTIL) in Q1 2025, closing a stake of 15,534 shares — an estimated $59.2K sold.

UBS O'Connor first reported a position in DTIL in Q2 2022 and held it in 10 quarters. The position peaked at $704K in Q2 2022. 48 funds tracked by Wall St. Rank hold DTIL as of Q1 2025.

  • UBS O'Connor reported no remaining Precision BioSciences position as of Q1 2025 after selling out during the quarter.
  • UBS O'Connor sold 15,534 Precision BioSciences shares in Q1 2025, an estimated $59.2K.
  • UBS O'Connor first reported a position in Precision BioSciences in Q2 2022 and held it in 10 quarters.
  • UBS O'Connor's Precision BioSciences position peaked at $704K in Q2 2022.
  • 48 funds tracked by Wall St. Rank held Precision BioSciences as of Q1 2025.

Based on UBS O'Connor's 13F filing for Q1 2025, filed 15 May 2025.